IP Library Granted Patent US 8,685,891
Granted Patent B2
US 8,685,891 · App. 13/391,910 · Granted Apr 1, 2014

Method and assay for determining FAS expression

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,685,891
App. No.
13/391,910
Granted
Apr 1, 2014
Kind
B2
Abstract

Methods and immunoassays for the determination of fatty acid synthase (FAS) expression in patients having or suspected of having a proliferative disorder, especially prostate cancer, are disclosed. The sensitive method and assay detect the level of expression of FAS in a biological sample using antibodies that are highly specific for FAS. The method and assay can be used to monitor the progression of cancer, and/or to predict the efficacy of certain treatments or the likelihood of recurrence of the cancer.

Claims (10)

1. A method for monitoring the progression of cancer, comprising the steps of:

i. contacting a biological sample from a cancer patient with a first purified anti-FAS antibody that is specific for the peptide encoded by SEQ ID NO 5, under conditions sufficient to form a conjugate of the antibody and FAS protein in the sample;

ii. contacting the conjugate formed in step (a) with a second anti-FAS antibody, wherein the second antibody is tagged with a detectable label;

iii. determining the amount of FAS protein present in the sample; and

iv. correlating the amount of FAS present in the sample with aggressiveness of the cancer;

wherein the presence of a high level of FAS in the sample is indicative of an aggressive form of the cancer.

2. The method of claim 1 , wherein the biological sample is serum.

3. The method of claim 1 , wherein the detectable labels are fluorescent labels.

4. The method of claim 1 , wherein the first antibody is disposed on a substrate.

5. The method of claim 4 , wherein the substrate is a microtiter plate.

Assignments (2)
COURT ORDER Recorded Jun 1, 2017
From: NUCLEA BIOTECHNOLOGIES, INC.
To: NMDX, LLC
Reel/Frame 042562/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2012
From: MURACA, PATRICK J.
To: NUCLEA BIOTECHNOLOGIES, INC.
Reel/Frame 028585/0393 →